R-pil

Ramipril

COMPOSITION

R-pil 1.25 mg Tablet : Each film coated tablet contains Ramipril BP 1.25 mg.
R-pil 2.5 mg Tablet : Each film coated tablet contains Ramipril BP 2.5 mg.
R-pil 5 mg Tablet : Each film coated tablet contains Ramipril BP 5 mg.

PHARMACOLOGY

R-pil is an angiotensin converting enzyme (ACE) inhibitor. This prodrug itself is a poor inhibitor of ACE but is rapidly hydrolysed after absorption to active metabolite ramipril. Following oral administration of ramipril, peak plasma concentration of ramipril is reached within one hour. The extent of absorption is at least 50-60% and is not significantly influenced by the presence of food in the GI tract although the rate of absorption is reduced.

INDICATION AND USES

1. Mild to severe hypertension, where it may be used alone or in combination with thiazide diuretics
2. Congestive heart failure
3. To reduce the risk of stroke, myocardial infarction and death from cardiovascular events in patients with a history of cardiovascular diseases
4. Proteinuric non-diabetic nephropathy

DOSAGE AND ADMINISTRATION

Dosage of R-pil must be adjusted according to the patient's tolerance and response. For the management of hypertension in adults not receiving a diuretic, the usual initial dose of Ramipril is 1.25-2.5 mg once daily. Dosage generally is adjusted no more rapidly than at 2-week intervals. The usual maintenance dosage in adults is 2.5-20 mg daily given as a single dose or in 2 divided doses daily. If BP is not controlled with ramipril alone, a diuretic may be added.

CONTRAINDICATION

Ramipril is contraindicated in patients who are hypersensitive to any component of this product and in patients with a history of angioedema related to previous treatment with a ACE inhibitor.

SIDE EFFECT

Ramipril is generally well tolerated. Dizziness, headache, fatigue and asthenia are commonly reported side effects.
Warnings : Ramipril should be used with caution in patients with impaired renal function, hyperkalemia, hypotension, surgery/anesthesia and impaired hepatic function.

DRUG INTERACTIONS

Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. If this is not possible, the starting dose should be reduced.

USE IN PREGNANCY

Pregnancy should be excluded before start of treatment with ramipril and avoided during treatment. However, if pregnancy is detected, ramipril should be discontinued as early as possible unless continued use is considered life saving.

USE IN LACTATION

Ramipril should not be used during lactation.

USE IN PEDIATRIC PATIENTS

Safely and effectiveness in pediatric patients have not been established.

STORAGE CONDITION

Store at cool & dry place, Protect from light and moisture.

COMMERCIAL PACK

R-pil 1.25 mg Tablet : Each pack contains 30 tablets in blister pack.
R-pil 2.5 mg Tablet : Each pack contains 30 tablets in blister pack.
R-pil 5 mg Tablet : Each pack contains 30 tablets in blister pack.

Manufactured by
BIOPHARMA LIMITED
A-116, BSCIC Industrial Estate
TONGI, GAZIPUR, BANGLADESH

For further query on the use of this medicine, consult to a registered Doctor or Pharmacist.